KOSDAQCosmetics352480

C&C International

₩16,890▲ 1.99%2026-11-18 close
Market Cap
₩230.2B
Turnover
₩75,684,405
Volume
4.5K
Shares out.
13.6M
PER
—
PBR
0.6×
EPS
-₩605
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Sales Up, Margins Down: Color-cosmetics ODM Swings to Quarterly Loss

C&C International's sales kept rising through 2025, but its operating margin fell from 14.6% in 2023 to 7.7% in 2025, and it posted an operating loss of KRW 440 million in Q3 2026.

  1. 1

    2025 revenue of KRW 288.5 billion was the largest year in 2022–2025, while operating profit fell 23.5% year on year to KRW 22.2 billion.

  2. 2

    Operating margin slid from 14.6% in 2023 to 7.7% in 2025, so sales growth has not carried through to profitability.

  3. 3

    Attributable net losses continued in Q2 and Q3 2026, and the last four quarters total a KRW 7.36 billion attributable net loss.

  4. 4

    The debt-to-equity ratio fell to 23.5% at end-2025 from 48.3% in 2023, with total equity of KRW 354.4 billion.

  5. 5

    The price-to-book ratio sits below 1x, but PER cannot be calculated because the last four quarters were net losses.

02

Business structure

C&C International is a color-cosmetics ODM (outsourced development and manufacturing) company founded in 1997 and listed on KOSDAQ in May 2021. Lip, base and eye makeup development and manufacturing are its core lines.

As of reporting in late 2024, the company was said to serve more than 120 domestic and overseas brand clients, including Amorepacific, L'Oréal, CLIO Cosmetics and Dior.

In Q4 2025 product-line sales, taken from the company's earnings release, were KRW 45.5 billion for lip products (up 38.3% year on year), KRW 16.4 billion for base products (up 31%) and KRW 10.5 billion for eye products (up 6.4%).

Lip products accounted for 62.2% of total sales in Q1 2025, making them the largest category. By region in Q2 2025, domestic sales were KRW 39.1 billion (down 26.3% year on year), North America and Europe sales were KRW 23.6 billion (up 15.7%), and Asia sales were KRW 11.3 billion (up 61.4%).

The China-based subsidiary's sales rose 175% year on year in the same quarter, according to the company. A April 2024 FnGuide tally grouped C&C International with Cosmax, Kolmar Korea and Cosmecca Korea as the four largest domestic cosmetics manufacturers.

In May 2025 the company resolved a KRW 145 billion third-party allotment rights offering to Ascent Equity Partners, which was disclosed as expected to give the fund a 41.2% stake.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩75.4B₩6.9B9.2%
2025Q4₩73.2B₩1B1.4%
2026Q1₩70.8B₩3B4.2%
2026Q2₩73.3B₩1.6B2.2%
2026Q3₩70.8B-₩400M−0.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩130.6B₩17.5B₩16.5B13.4%12.3%33.4%
2023₩220.3B₩32.1B₩31.4B14.6%18.2%48.3%
2024₩282.9B₩29B₩32.4B10.2%15.8%43.4%
2025₩288.5B₩22.2B₩14.3B7.7%4.0%23.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Annual results moved in different directions for sales and profit.

Revenue went from KRW 130.6 billion in 2022 to KRW 220.3 billion in 2023 (up 68.7% year on year), KRW 282.9 billion in 2024 (up 28.4%) and KRW 288.5 billion in 2025 (up 2.0%), rising three years in a row from 2023 through 2025, with 2025 the largest year of 2022–2025.

Operating profit went from KRW 17.5 billion in 2022 to KRW 32.1 billion in 2023 (up 83.9%), the peak year, then fell to KRW 29 billion in 2024 (down 9.7%) and KRW 22.2 billion in 2025 (down 23.5%), declining two years in a row from 2024 through 2025.

Operating margin was 13.4% in 2022, 14.6% in 2023, 10.2% in 2024 and 7.7% in 2025. The company attributed 2023 results to higher order volumes from domestic and overseas clients, and it recorded about KRW 2.3 billion of management bonuses in Q4 2023.

By quarter, operating profit of KRW 6.9 billion in Q3 2025 dropped to KRW 1.04 billion in Q4 2025 (down 85.0% from the prior quarter).

In February 2026 Samsung Securities attributed weaker production efficiency to a higher share of new products and more small-batch, multi-SKU production, along with production disruption from a new ERP system.

Operating profit rebounded to KRW 2.97 billion in Q1 2026 (up 186.1% from the prior quarter), then fell to KRW 1.6 billion in Q2 (down 46.1%) and turned into an operating loss of KRW 440 million in Q3.

Attributable net income went from KRW 7.46 billion in Q3 2025 and KRW 1.55 billion in Q4 2025 to KRW 5.08 billion in Q1 2026, then to attributable net losses of KRW 6.23 billion in Q2 and KRW 7.76 billion in Q3, two straight loss quarters. Q3 2026 revenue of KRW 70.8 billion was down 6.1% year on year. Attributable net income for 2025 was KRW 14.3 billion, down 56.0% from KRW 32.4 billion in 2024.

05

Industry analysis

Color-cosmetics ODM orders can swing sharply with brand owners' new-product cycles and orders from overseas indie brands. In November 2024 DB Financial Investment said visibility on earnings across the cosmetics sector had weakened and that concern over competition in the market had grown.

The same report also pointed to high dependence on a few key countries and a small number of clients. An April 2024 FnGuide tally projected that Q1 operating profit at the four largest domestic cosmetics manufacturers could rise by as much as double year on year.

Listed peers that are compared directly in ODM include Cosmax, Kolmar Korea and Cosmecca Korea. C&C International is weighted toward color cosmetics, which gives lip products a larger share than at these peers. Skincare expansion moved quickly, with sales reported as up 364.9% from the prior quarter in Q2 2025.

On the May 2025 ownership change, brokers pointed to both synergy expectations for the overseas strategy and dilution concerns. The shift toward overseas clients is also visible in Q1 2025 Europe and North America sales of KRW 22.1 billion, up 31.5% from the prior quarter.

The February 2026 analysis focused on the point that production efficiency can weaken in the early stage of diversifying the client base.

06

Outlook

The company presented joint projects with global mega brands and high-value new product launches for the second half of 2025 as plans, and said it was pursuing sales diversification through a wider skincare line.

In a February 2026 analysis, Samsung Securities noted that none of the recently launched new products showed a clear path to large repeat orders in the short term.

Q3 2026 revenue fell 6.1% year on year and turned into an operating loss, so the next checkpoint is whether the planned collaborations and new products show up as a sales recovery. The China-based subsidiary's sales rose 175% year on year in Q2 2025, making it one pillar of overseas growth.

The pace at which new overseas client volume reaches reported results should be checked in quarterly sales. On the production side, normalization of the disruption linked to the new ERP system is a precondition for recovering operating margin. The next periodic report is the 2026 annual report, due by late March 2027.

That filing will fix full-year 2026 sales and operating margin and will also show the largest shareholder structure and any change in management direction. Based on last year's timing, the Q4 2026 preliminary results would likely come around mid-February 2027. Whether operating margin recovers from 7.7% in 2025 is the key metric to watch in the next periodic report.

07

Valuation

PER
—
PBR
0.6×
ROE
-2.7%
EPS
-₩605
BPS
₩31,358
Dividend per share
₩0

The stock trades below 1x book value, which is a low multiple on an asset basis. However, PER cannot be calculated because the last four quarters were net losses.

Any reading of the multiples depends on how quickly earnings recover, so comparing with the 2023 operating profit level is the reference point on past earnings. Cash returns through dividends are currently low.

Because the May 2025 rights offering increased the number of shares, per-share comparisons should account for that dilution. On the strength side, the low multiple relative to book value and the lower debt ratio stand out.

On the weakness side, the swing to losses and large quarter-to-quarter earnings volatility stand out. These two sets of factors should be weighed equally, and the direction of valuation will depend on whether earnings recover.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Sustained top-line growth

Revenue rose three years in a row from 2023 through 2025, reaching KRW 288.5 billion in 2025, the largest year of 2022–2025. In Q4 2025, lip product sales rose 38.3% year on year and base product sales rose 31%. Sales of the China-based subsidiary rose 175% year on year in Q2 2025. Broadening both product lines and regions is supporting the top-line growth.

Stronger balance sheet

The debt-to-equity ratio fell from 48.3% in 2023 to 23.5% at end-2025, with total liabilities of KRW 83.4 billion. Operating cash flow was positive in every year from 2022 to 2025, at KRW 8.83 billion, KRW 22.8 billion, KRW 44.2 billion and KRW 26.7 billion. Total equity of KRW 354.4 billion supports a business that does not depend on heavy borrowing.

Quarterly profit rebound

Operating profit rebounded to KRW 2.97 billion in Q1 2026 (up 186.1% from the prior quarter) after KRW 1.04 billion in Q4 2025. Revenue held at KRW 70.8 billion in the same quarter. Europe and North America sales reached KRW 22.1 billion in Q1 2025, up 31.5% from the prior quarter. The timing of the turn in quarterly profit is now visible in the reported figures.

09

Bear factors

Shrinking profitability

Operating margin fell from 14.6% in 2023 to 10.2% in 2024 and 7.7% in 2025, declining two years in a row. Operating profit in 2025 was KRW 22.2 billion, down 23.5% year on year. Q3 2026 produced an operating loss of KRW 440 million. Sales rising without profit following is the clearest weakness.

Continued quarterly losses

Attributable net losses were KRW 6.23 billion in Q2 2026 and KRW 7.76 billion in Q3, two straight loss quarters. The last four quarters total a KRW 7.36 billion attributable net loss. Sales declining alongside losses makes the timing of a recovery uncertain.

Production efficiency and client concentration

In February 2026 Samsung Securities attributed weaker production efficiency to more small-batch, multi-SKU production and a new ERP system. In November 2024 DB Financial Investment pointed to high dependence on key countries and a few clients. Together, these factors mean order swings from a single client can move quarterly results sharply.

10

Risk factors

Ownership and capital changes

The KRW 145 billion third-party allotment rights offering decided in May 2025 dilutes existing shareholders. How management direction shifts as Ascent Equity Partners takes its stake is a point that remains to be confirmed through disclosures. Brokers described the matter as one to approach from a long-term perspective.

Production efficiency and systems transition

In February 2026 analysis, production disruption was linked to a rise in multi-SKU, small-batch output and the introduction of a new ERP system. These factors were cited as the background to Q4 2025 operating profit falling to KRW 1.04 billion. Whether production efficiency has recovered is not yet proven by the Q3 2026 operating loss.

Client concentration and overseas order volatility

In November 2024 high dependence on key countries and a few clients was flagged. If new overseas client volume does not convert into large repeat orders, quarterly sales could swing. Q3 2026 revenue was down 6.1% year on year.

11

What to watch next

  1. Around mid-February 2027

    Preliminary Q4 2026 results. Last year's Q4 preliminary results were disclosed on February 13, 2026, so a similar timing is the reference. The checkpoints are whether the operating loss continues and whether attributable net losses extend to a third straight quarter.

  2. Late March 2027

    Deadline for the 2026 annual report. Full-year 2026 sales, operating profit and operating margin will be fixed in the periodic report, and the largest shareholder structure and ownership changes can be checked in the same filing.

  3. Around early May 2027

    Q1 2027 preliminary results. Q1 2025 results were announced on May 9. The checkpoints are whether quarterly operating profit returns to a profit and whether new client orders show up in revenue.

  4. Around mid-August 2027

    Deadline for the 2027 half-year report, 45 days after the period ends. Cumulative first-half operating margin and attributable net income trends can be checked against the periodic report figures.

12

Overall view

C&C International's sales grew from KRW 130.6 billion in 2022 to KRW 288.5 billion in 2025, but profitability has trended lower since 2023. Operating margin fell from 14.6% in 2023 to 7.7% in 2025, and Q3 2026 turned into an operating loss of KRW 440 million.

Strengths include a debt-to-equity ratio of 23.5% at end-2025, positive operating cash flow in every year from 2022 to 2025, the Q1 2026 profit rebound, and growth in the China subsidiary and overseas clients.

Weaknesses include a combined attributable net loss of KRW 7.36 billion over the last four quarters, weaker production efficiency and ERP-related disruption, and reliance on a few key clients. On the share price side, the stock trades below 1x book value while PER cannot be calculated, and both facts coexist.

The next checkpoint is whether full-year operating margin recovers in the 2026 annual report, due by late March 2027. After that, the 2027 first-half results and half-year report will show whether loss quarters continue and whether the joint projects with overseas clients translate into sales.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. cosinkorea.com
  2. m.thinkpool.com
  3. digitaltoday.co.kr
  4. news.nate.com
  5. pharmnews.com
  6. enetnews.co.kr
  7. beautynury.com
  8. joongangenews.com
  9. sedaily.com
  10. mt.co.kr
  11. hankyung.com
  12. mt.co.kr
  13. mt.co.kr
  14. hankyung.com
  15. dailyinvest.kr
  16. hanwhawm.com
  17. m.thinkpool.com
  18. hankyung.com

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis